Correction to: Asperger’s syndrome: diagnosis, comorbidity and therapy (Expert Review of Neurotherapeutics, (2015), 15, 3, (281-293), 10.1586/14737175.2015.1009898);Asperger's syndrome: Diagnosis, comorbidity and therapy

Expert Review of Neurotherapeutics

Volumn 15, Issue 3, 2015, Pages 281-293

  Tarazi, F I ^a   Sahli, Z T ^a,b   Pleskow, J ^c   Mousa, S A ^c  

^a MCLEAN HOSPITAL   (United States)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^c ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Asperger's syndrome; autistic spectrum disorders; cognitive behavioral therapy; comorbid disorders; pharmacotherapy; symptoms

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BUMETANIDE; CENTRAL STIMULANT AGENT; CITALOPRAM; CLONIDINE; ESCITALOPRAM; GUANFACINE; OXYTOCIN; RISPERIDONE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT;

ANXIETY DISORDER; ARTICLE; ASPERGER SYNDROME; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; BIPOLAR DISORDER; COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; DRUG THERAPY; EXPERIMENTAL THERAPY; GILLES DE LA TOURETTE SYNDROME; HERB; HUMAN; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; STEM CELL TRANSPLANTATION; ANXIETY; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; COMPLICATION; DIFFERENTIAL DIAGNOSIS; QUALITY OF LIFE;

ADRENERGIC ALPHA-AGONISTS; ANTIPSYCHOTIC AGENTS; ANXIETY; ASPERGER SYNDROME; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DEPRESSION; DIAGNOSIS, DIFFERENTIAL; HUMANS; QUALITY OF LIFE;

EID: 84923320358     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2015.1039795     Document Type: Erratum

References (120)

1. Kanner L. Autistic disturbances of affective contact. Nervous Child 1943;2:217-50
2. Hippler K, Klicpera C. A retrospective analysis of the clinical case records of 'autistic psychopaths' diagnosed by Hans Asperger and his team at the University Children's Hospital, Vienna. Philos Trans R Soc Lond B Biol Sci 2003;358:291-301
3. Lord C, Cook EH, Leventhal BL, Amaral DG. Autism spectrum disorders. Neuron 2000;28:355-63
4. Filipek PA, Accardo PJ, Baranek GT, et al. The screening and diagnosis of autistic spectrum disorders. J Autism Dev Disord 1999;29:439-84
5. Tebartz van Elst L, Pick M, Biscaldi M, et al. High-functioning autism spectrum disorder as a basic disorder in adult psychiatry and psychotherapy: psychopathological presentation, clinical relevance and therapeutic concepts. Eur Arch Psychiatry Clin Neurosci 2013;263(Suppl 2):S189-96
6. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th edition. DSM-5 VA: American Psychiatric Association; Arlington: 2013
7. Mahjouri S, Lord CE. What the DSM-5 portends for research, diagnosis, and treatment of autism spectrum disorders. Curr Psychiatry Rep 2012;14:739-47
8. Halfon N, Kuo AA. What DSM-5 could mean to children with autism and their families. JAMA Pediatr 2013;167:608-13
9. Huerta M, Bishop SL, Duncan A, et al. Application of DSM-5 criteria for autism spectrum disorder to three samples of children with DSM-IV diagnoses of pervasive developmental disorders. Am J Psychiatry 2012;169:1056-64
10. Kulage KM, Smaldone AM, Cohn EG. How will DSM-5 affect autism diagnosis? A systematic literature review and meta-analysis. J Autism Dev Disord 2014;44:1918-32
11. Blumberg SJ, Bramlett MD, Kogan MD, et al. Changes in prevalence of parent-reported autism spectrum disorder in school-aged US Children: 2007 to 2011-2012. Natl Health Stat Report 2013;65:1-11; 1 p following 11
12. Newschaffer CJ, Croen LA, Daniels J, et al. The epidemiology of autism spectrum disorders. Annu Rev Public Health 2007;28: 235-58
13. Duffy FH, Shankardass A, McAnulty GB, Als H. The relationship of Asperger's syndrome to autism: a preliminary EEG coherence study. BMC Med 2013;11:175
14. Lotspeich LJ, Kwon H, Schumann CM, et al. Investigation of neuroanatomical differences between autism and Asperger syndrome. Arch Gen Psychiatry 2004;61: 291-8
15. Ehlers S, Gillberg C. The epidemiology of Asperger syndrome. A total population study. J Child Psychol Psychiatry 1993;34: 1327-50
16. Fernandez-Jaen A, Martin Fernandez-Mayoralas D, Calleja-Perez B, Munoz-Jareno N. [Asperger syndrome: diagnosis and treatment]. Rev Neurol 2007;44(Suppl 2):S53-5
17. McPartland J, Klin A. Asperger's syndrome. Adolesc Med Clin 2006;17:771-88
18. McConachie H, Le Couteur A, Honey E. Can a diagnosis of Asperger syndrome be made in very young children with suspected autism spectrum disorder? J Autism Dev Disord 2005;35:167-76
19. Szatmari P, Bryson SE, Boyle MH, et al. Predictors of outcome among high functioning children with autism and Asperger syndrome. J Child Psychol Psychiatry 2003;44:520-8
20. Woodbury-Smith MR, Volkmar FR. Asperger syndrome. Eur Child Adolesc Psychiatry 2009;18:2-11
21. Matson JL, Wilkins J, Boisjoli JA, Smith KR. The validity of the autism spectrum disorders-diagnosis for intellectually disabled adults (ASD-DA). Res Dev Disabil 2008;29:537-46
22. World Health Organization. The ICD-10 classification of mental and behavioral disorders: diagnostic criteria for research. World Health Organization; Geneva: 1993
23. Campbell JM. Diagnostic assessment of Asperger's disorder: a review of five third-party rating scales. J Autism Dev Disord 2005;35:25-35
24. Aman MG, Singh NN, Stewart AW, Field CJ. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 1985;89:485-91
25. Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont) 2007;4:28-37
26. Abdallah MW, Greaves-Lord K, Grove J, et al. Psychiatric comorbidities in autism spectrum disorders: findings from a Danish Historic Birth Cohort. Eur Child Adolesc Psychiatry 2011;20:599-601
27. Leyfer OT, Folstein SE, Bacalman S, et al. Comorbid psychiatric disorders in children with autism: interview development and rates of disorders. J Autism Dev Disord 2006;36:849-61
28. Mazzone L, Ruta L, Reale L. Psychiatric comorbidities in asperger syndrome and high functioning autism: diagnostic challenges. Ann Gen Psychiatry 2012;11:16
29. Green J, Gilchrist A, Burton D, Cox A. Social and psychiatric functioning in adolescents with Asperger syndrome compared with conduct disorder. J Autism Dev Disord 2000;30:279-93
30. Weiss MD, Weiss JR. A guide to the treatment of adults with ADHD. J Clin Psychiatry 2004;65(Suppl 3):27-37
31. Roy M, Dillo W, Bessling S, et al. Effective methylphenidate treatment of an adult Aspergers Syndrome and a comorbid ADHD: a clinical investigation with fMRI. J Atten Disord 2009;12:381-5
32. Toth K, King BH. Asperger's syndrome: diagnosis and treatment. Am J Psychiatry 2008;165:958-63
33. Stewart ME, Barnard L, Pearson J, et al. Presentation of depression in autism and Asperger syndrome: a review. Autism 2006;10:103-16
34. Gupta RK. Major depression: an illness with objective physical signs. World J Biol Psychiatry 2009;10:196-201
35. Whitehouse AJ, Durkin K, Jaquet E, Ziatas K. Friendship, loneliness and depression in adolescents with Asperger's Syndrome. J Adolesc 2009;32:309-22
36. White SW, Oswald D, Ollendick T, Scahill L. Anxiety in children and adolescents with autism spectrum disorders. Clin Psychol Rev 2009;29:216-29
37. Lugnegard T, Hallerback MU, Gillberg C. Psychiatric comorbidity in young adults with a clinical diagnosis of Asperger syndrome. Res Dev Disabil 2011;32: 1910-17
38. Russell E, Sofronoff K. Anxiety and social worries in children with Asperger syndrome. Aust N Z J Psychiatry 2005;39:633-8
39. Wood J, Gadow K. Exploring the nature and function of anxiety in youth with autism spectrum disorders. Clin Psychol Sci Pract 2010;17:281-92
40. Wood JJ, Drahota A, Sze K, et al. Cognitive behavioral therapy for anxiety in children with autism spectrum disorders: a randomized, controlled trial. J Child Psychol Psychiatry 2009;50:224-34
41. Denckla MB. Attention-deficit hyperactivity disorder (ADHD) comorbidity: a case for "pure" Tourette syndrome? J Child Neurol 2006;21:701-3
42. Singer HS, Hong JJ, Yoon DY, Williams PN. Serum autoantibodies do not differentiate PANDAS and Tourette syndrome from controls. Neurology 2005;65:1701-7
43. Lombroso PJ, Scahill L. Tourette syndrome and obsessive-compulsive disorder. Brain Dev 2008;30:231-7
44. Stein DJ, Denys D, Gloster AT, et al. Obsessive-compulsive disorder: diagnostic and treatment issues. Psychiatr Clin North Am 2009;32:665-85
45. Bejerot S. An autistic dimension: a proposed subtype of obsessive-compulsive disorder. Autism 2007;11:101-10
46. Morriss RK, Faizal MA, Jones AP, et al. Interventions for helping people recognise early signs of recurrence in bipolar disorder. Cochrane Database Syst Rev 2007; CD004854
47. Benazzi F. Bipolar disorder-focus on bipolar II disorder and mixed depression. Lancet 2007;369:935-45
48. Gutkovich ZA, Carlson GA, Carlson HE, et al. Asperger's disorder and co-morbid bipolar disorder: diagnostic and treatment challenges. J Child Adolesc Psychopharmacol 2007;17:247-55
49. Munesue T, Ono Y, Mutoh K, et al. High prevalence of bipolar disorder comorbidity in adolescents and young adults with high-functioning autism spectrum disorder: a preliminary study of 44 outpatients. J Affect Disord 2008;111:170-5
50. Remschmidt H, Theisen FM. Schizophrenia and related disorders in children and adolescents. J Neural Transm Suppl 2005; 121-41
51. Lugnegard T, Unenge Hallerback M, Hjarthag F, Gillberg C. Social cognition impairments in Asperger syndrome and schizophrenia. Schizophr Res 2013;143: 277-84
52. Gottlieb S. Methylphenidate works by increasing dopamine levels. BMJ 2001;322:259
53. Greenhill LL, Pliszka S, Dulcan MK, et al. Summary of the practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2001;40:1352-5
54. Greenhill L, Beyer DH, Finkleson J, et al. Guidelines and algorithms for the use of methylphenidate in children with Attention-Deficit/Hyperactivity Disorder. J Atten Disord 2002;6(Suppl 1):S89-100
55. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 2005;62:1266-74
56. Stigler KA, Desmond LA, Posey DJ, et al. A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. J Child Adolesc Psychopharmacol 2004;14:49-56
57. Newcorn JH, Schulz K, Harrison M, et al. Alpha 2 adrenergic agonists. Neurochemistry, efficacy, and clinical guidelines for use in children. Pediatr Clin North Am 1998;45:1099-22, viii
58. Fankhauser MP, Karumanchi VC, German ML, et al. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry 1992;53:77-82
59. Ming X, Gordon E, Kang N, Wagner GC. Use of clonidine in children with autism spectrum disorders. Brain Dev 2008;30: 454-60
60. Kornfield R, Watson S, Higashi AS, et al. Effects of FDA advisories on the pharmacologic treatment of ADHD, 2004-2008. Psychiatr Serv 2013;64:339-46
61. Posey DJ, Puntney JI, Sasher TM, et al. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol 2004;14:233-41
62. Baldessarini R, Tarazi F. Pharmacotherapy of psychosis and mania. In: Brunton LL, Lazo JS, Parker K, editors. The Pharmacological Basis of Therapeutics. 11th edition. McGraw-Hill; New York: 2005. pp.461-500
63. Crystal S, Olfson M, Huang C, et al. Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Aff (Millwood) 2009;28:w770-81
64. Marcus RN, Owen R, Kamen L, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 2009;48: 1110-19
65. Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 2009;124:1533-40
66. Stigler KA, Diener JT, Kohn AE, et al. Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study. J Child Adolesc Psychopharmacol 2009;19:265-74
67. Stavrakaki C, Antochi R, Emery PC. Olanzapine in the treatment of pervasive developmental disorders: a case series analysis. J Psychiatry Neurosci 2004;29: 57-60
68. Kemner C, Willemsen-Swinkels SH, de Jonge M, et al. Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol 2002;22:455-60
69. Malone RP, Cater J, Sheikh RM, et al. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry 2001;40:887-94
70. Potenza MN, Holmes JP, Kanes SJ, McDougle CJ. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 1999;19:37-44
71. McDougle CJ, Scahill L, Aman MG, et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 2005;162:1142-8
72. Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004;114:e634-41
73. Luby J, Mrakotsky C, Stalets MM, et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol 2006;16:575-87
74. Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol 2006;21:450-5
75. McDougle CJ, Kem DL, Posey DJ. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 2002;41: 921-7
76. Cohen SA, Fitzgerald BJ, Khan SR, Khan A. The effect of a switch to ziprasidone in an adult population with autistic disorder: chart review of naturalistic, open-label treatment. J Clin Psychiatry 2004;65:110-13
77. Malone RP, Delaney MA, Hyman SB, Cater JR. Ziprasidone in adolescents with autism: an open-label pilot study. J Child Adolesc Psychopharmacol 2007;17:779-90
78. Namerow LB, Thomas P, Bostic JQ, et al. Use of citalopram in pervasive developmental disorders. J Dev Behav Pediatr 2003;24:104-8
79. Owley T, Brune CW, Salt J, et al. A pharmacogenetic study of escitalopram in autism spectrum disorders. Autism Res 2010;3:1-7
80. Owley T, Walton L, Salt J, et al. An open-label trial of escitalopram in pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 2005;44:343-8
81. Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004;5:553-64
82. Gould TD, Quiroz JA, Singh J, et al. Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Mol Psychiatry 2004;9:734-55
83. Hollander E, Soorya L, Wasserman S, et al. Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. Int J Neuropsychopharmacol 2006;9:209-13
84. Hellings JA,Weckbaugh M, Nickel EJ, et al. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2005;15:682-92
85. Hollander E, Chaplin W, Soorya L, et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology 2010;35:990-8
86. Dzhala VI, Talos DM, Sdrulla DA, et al. NKCC1 transporter facilitates seizures in the developing brain. Nat Med 2005;11: 1205-13
87. Cherubini E, Ben-Ari Y. The immature brain needs GABA to be excited and hyper-excited. J Physiol 2011;589:2655-6
88. Pizzarelli R, Cherubini E. Alterations of GABAergic signaling in autism spectrum disorders. Neural Plast 2011;2011:297153
89. Lemonnier E, Degrez C, Phelep M, et al. A randomised controlled trial of bumetanide in the treatment of autism in children. Transl Psychiatry 2012;2:e202
90. Owens G, Granader Y, Humphrey A, Baron-Cohen S. LEGO therapy and the social use of language programme: an evaluation of two social skills interventions for children with high functioning autism and Asperger Syndrome. J Autism Dev Disord 2008;38:1944-57
91. Tanaka JW, Wolf JM, Klaiman C, et al. Using computerized games to teach face recognition skills to children with autism spectrum disorder: the Let's Face It! program. J Child Psychol Psychiatry 2010;51:944-52
92. Stichter JP, Herzog MJ, Visovsky K, et al. Social competence intervention for youth with Asperger Syndrome and high-functioning autism: an initial investigation. J Autism Dev Disord 2010;40:1067-79
93. Beaumont R, Sofronoff K. A multi-component social skills intervention for children with Asperger syndrome: the Junior Detective Training Program. J Child Psychol Psychiatry 2008;49:743-53
94. Kandalaft MR, Didehbani N, Krawczyk DC, et al. Virtual reality social cognition training for young adults with high-functioning autism. J Autism Dev Disord 2013;43:34-44
95. Blackburn IM, Roxborough HM, Muir WJ, et al. Perceptual and physiological dysfunction in depression. Psychol Med 1990;20:95-103
96. Butler AC, Chapman JE, Forman EM, Beck AT. The empirical status of cognitive-behavioral therapy: a review of meta-analyses. Clin Psychol Rev 2006;26: 17-31
97. Sofronoff K, Attwood T, Hinton S, Levin I. A randomized controlled trial of a cognitive behavioural intervention for anger management in children diagnosed with Asperger syndrome. J Autism Dev Disord 2007;37:1203-14
98. Anderson SW, Booker MB Jr. Cognitive behavioral therapy versus psychosurgery for refractory obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci 2006;18:129
99. DeRubeis RJ, Gelfand LA, Tang TZ, Simons AD. Medications versus cognitive behavior therapy for severely depressed outpatients: mega-analysis of four randomized comparisons. Am J Psychiatry 1999;156:1007-13
100. Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000;342:1462-70
101. Rupke SJ, Blecke D, Renfrow M. Cognitive therapy for depression. Am Fam Physician 2006;73:83-6
102. Landgraf R, Neumann ID. Vasopressin and oxytocin release within the brain: a dynamic concept of multiple and variable modes of neuropeptide communication. Front Neuroendocrinol 2004;25:150-76
103. Andari E, Duhamel JR, Zalla T, et al. Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Proc Natl Acad Sci USA 2010;107: 4389-94.
104. Hollander E, Novotny S, Hanratty M, et al. Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders. Neuropsychopharmacology 2003;28:193-8
105. Bartz JA, Hollander E. Oxytocin and experimental therapeutics in autism spectrum disorders. Prog Brain Res 2008;170:451-62
106. Ichim TE, Solano F, Glenn E, et al. Stem cell therapy for autism. J Transl Med 2007;5:30
107. Taguchi A, Soma T, Tanaka H, et al. Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J Clin Invest 2004;114:330-8
108. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105: 1815-22
109. Aizawa R, Kanbayashi T, Saito Y, et al. Effects of Yoku-kan-san-ka-chimpi-hange on the sleep of normal healthy adult subjects. Psychiatry Clin Neurosci 2002;56:303-4
110. Iwasaki K, Satoh-Nakagawa T, Maruyama M, et al. A randomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients. J Clin Psychiatry 2005;66:248-52
111. Miyaoka T, Wake R, Furuya M, et al. Yokukansan (TJ-54) for treatment of pervasive developmental disorder not otherwise specified and Asperger's disorder: a 12-week prospective, open-label study. BMC Psychiatry 2012;12:215
112. Yamaguchi T, Tsujimatsu A, Kumamoto H, et al. Anxiolytic effects of yokukansan, a traditional Japanese medicine, via serotonin 5-HT1A receptors on anxiety-related behaviors in rats experienced aversive stress. J Ethnopharmacol 2012;143:533-9
113. Miyaoka T, Horiguchi J. Clinical potential of yi-gan san (yokukansan) for the treatment of psychiatric disorders. Curr Psychiatry Rev 2009;5:271-5
114. McAlonan GM, Daly E, Kumari V, et al. Brain anatomy and sensorimotor gating in Asperger's syndrome. Brain 2002;125: 1594-606
115. Kleinhans N, Akshoomoff N, Delis DC. Executive functions in autism and Asperger's disorder: flexibility, fluency, and inhibition. Dev Neuropsychol 2005;27: 379-401
116. Murphy DG, Critchley HD, Schmitz N, et al. Asperger syndrome: a proton magnetic resonance spectroscopy study of brain. Arch Gen Psychiatry 2002;59:885-91
117. Volkmar FR, Klin A, Pauls D. Nosological and genetic aspects of Asperger syndrome. J Autism Dev Disord 1998;28:457-63
118. Warrier V, Baron-Cohen S, Chakrabarti B. Genetic variation in GABRB3 is associated with Asperger syndrome and multiple endophenotypes relevant to autism. Mol Autism 2013;4:48
119. Durdiakova J, Warrier V, Baron-Cohen S, Chakrabarti B. Single nucleotide polymorphism rs6716901 in SLC25A12 gene is associated with Asperger syndrome. Mol Autism 2014;5:25
120. Simonoff E, Pickles A, Charman T, et al. Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry 2008;47:921-9